|  |  | CDC25B-Abs |  | |
---|---|---|---|---|---|
Characteristics | Total (n = 134) | OD(SD) | Positive cases n (%) | Negative cases n (%) | P |
Gender | Â | Â | Â | Â | Â |
   Male | 93 | 0.913(0.496) | 48 (51.6) | 45 (48.4) | 0.053 |
   Female | 41 | 0.921(0.431) | 28 (68.3) | 13 (31.7) |  |
Age (y) | Â | Â | Â | Â | Â |
   <60 | 73 | 0.871(0.491) | 44 (60.3) | 29 (47.5) | 0.231 |
   ≥60 | 61 | 0.968(0.458) | 32(52.5) | 29 (39.7) |  |
Stage | Â | Â | Â | Â | Â |
   I-II | 80 | 0.892(0.478) | 37 (46.3) | 43 (53.7) | 0.002 |
   III-IV | 54 | 0.958(0.481) | 39 (72.2) | 15 (27.8) |  |
pT classification | Â | Â | Â | Â | Â |
   T1-T2 | 48 | 0.904(0.482) | 28 (58.3) | 20 (41.7) | 0.461 |
   T3-T4 | 86 | 0.919(0.477) | 48 (55.8) | 38 (44.2) |  |
pN classification | Â | Â | Â | Â | Â |
   YES | 53 | 0.980(0.511) | 29 (54.7) | 24 (45.3) | 0.420 |
   NO | 81 | 0.873(0.451) | 47 (58.0) | 34 (42.0) |  |
Metastasis | Â | Â | Â | Â | Â |
   YES | 8 | 0.917(0.436) | 3 (37.5) | 5 (62.5) | 0.222 |
   NO | 126 | 0.932(0.484) | 73 (57.9) | 53 (42.1) |  |